Part of Series on Lash Serum Safety

(updated May 2026)

How to Grow Eyebrows: 8 Causes of Thinning and Real Fixes

Eyebrow thinning gets brushed off as a cosmetic inconvenience. It rarely is. The brow follicle is a distinct biological structure with its own anagen-to-telogen ratio, its own hormonal sensitivities, and its own failure modes. Many are entirely different from scalp hair loss. When brows thin, the cause is almost always biological. So is the fix.

Below, we work through eight documented causes of eyebrow thinning, each mapped to the underlying follicle mechanism, supported by peer-reviewed evidence published between 2020 and 2026, and bridged to what actually supports healthy brow growth at the cellular level.

The 8 Causes of Eyebrow Thinning

1. Over-plucking

The problem. Repeated mechanical extraction of brow hairs is still the leading cause of sparse brows in women aged 30 to 60. Eyebrow anagen spans only 2–3 months, versus 2–8 years on the scalp (Nguyen et al., Am J Clin Dermatol, 2023, PMID 36183302), leaving minimal recovery time between pluck cycles.

Mechanism. Chronic trauma to the dermal papilla suppresses Wnt/β-catenin signaling, the pathway responsible for driving follicle cells into the anagen phase. Over time, repeated insult causes fibrotic occlusion of the follicular ostium. Scar tissue forms at the pore, physically blocking regrowth. When follicle pores are still visible, recovery is possible. When they are closed, regrowth is unlikely without intervention.

Evidence. The 2023 comprehensive review by Nguyen, Hu, and Tosti confirmed that traumatic madarosis from repetitive plucking presents as irregular, patchy brow alopecia with hairs of varying lengths on trichoscopy, and that follicular unit viability determines reversibility (PMID 36183302). Histopathologic analysis consistently shows peri-follicular fibrosis in chronic cases.

Plume approach. Where follicle viability remains, the Q5 Peptide Complex (Biotinoyl Tripeptide-1, Myristoyl Pentapeptide-17) supports keratin gene expression in recovering cells, while the C2 Complex's cAMP-elevating mechanism (US Patent 11,045,444) supports dermal papilla activity in follicles with intact infrastructure.

2. Chronic Stress

The problem. Sustained psychological or physiological stress is a well-characterized trigger for telogen effluvium, the condition in which follicles prematurely exit the growth phase and enter prolonged rest. Brows shed at a delay of 6–12 weeks after the peak stress event, which makes the causal connection easy to miss.

Mechanism. Cortisol acts on dermal papilla cells to suppress Gas6, a secreted protein that normally signals hair follicle stem cells (HFSCs) to exit quiescence and begin a new growth cycle. In the landmark 2021 Nature study by Choi et al., elevated corticosterone kept hair follicle stem cells locked in an extended resting phase. Restoring Gas6 expression reactivated follicle cycling even under high-corticosterone conditions (Choi et al., Nature, 2021, PMID 33790465). The cortisol-Gas6 axis provides the first molecular explanation for why chronic, not acute, stress drives disproportionate hair cycle disruption.

Evidence. The 2021 Choi et al. findings (PMID 33790465) are the most mechanistically complete stress-hair study to date. The cortisol-Gas6-HFSC axis provides the first direct molecular explanation for why chronic rather than acute stress causes disproportionate hair cycle disruption.

Plume approach. Plume Elite's C2 Complex elevates intracellular cAMP in dermal papilla cells via forskolin, acting upstream of the follicle signaling cascades that stress suppresses. Q5 peptides support dermal papilla health during the recovery window.

3. Nutritional Deficiencies

The problem. Iron deficiency is the most common nutritional driver of diffuse hair loss in women of reproductive age, and affects brows as readily as the scalp. Vitamin D, zinc, and biotin each play distinct follicle roles. Their deficiencies can exist simultaneously and compound brow thinning.

Mechanism. Iron carries oxygen to follicle matrix cells during active growth; depletion collapses anagen prematurely and raises the telogen fraction. Vitamin D receptor (VDR) signaling in dermal papilla cells is required for the anagen-initiating Wnt pathway. Zinc deficiency has been specifically documented in madarosis (eyebrow and eyelash alopecia), with case reports showing complete regrowth after zinc supplementation in deficient patients (Nguyen et al., 2023, PMID 36183302). Biotin's role is more limited than often claimed: a 2024 review found supplementation unsupported in the absence of confirmed deficiency (Controversies of Micronutrients in Hair Loss, Cosmoderma, 2024).

Evidence. Iron, vitamin D, and vitamin C (for iron absorption) carry the strongest evidence base for confirmed-deficiency hair loss (Harvard Health, 2024). Zinc deficiency has a specific documented role in eyebrow and eyelash alopecia, distinguishing it from scalp-focused nutritional literature (PMID 36183302).

Plume approach. Biotinoyl Tripeptide-1 in the Q5 Peptide Complex provides targeted biotin delivery directly to the follicle surface, bypassing the limited systemic absorption debate entirely. This supports follicle keratin scaffolding at the local level, independent of dietary status.

4. Hormonal Changes

The problem. Hormonal disruption (through menopause, thyroid dysfunction, PCOS, or exogenous hormone changes) affects brows through several convergent mechanisms. The lateral third is most vulnerable. The reasons are anatomical and hormonal at once.

Mechanism. Estrogen extends follicle anagen duration by amplifying IGF-1 signaling in dermal papilla cells (Trüeb, Hormonal Effects on Hair Follicles, Skin Appendage Disorders, 2020, PMID 32765998). When estrogen declines, IGF-1 activity falls and androgen sensitivity rises, shortening anagen and accelerating follicle miniaturization. Thyroid hormone deficiency compounds this: loss of the outer third of the brow Hertoghe's sign (also called Queen Anne's sign) is a classic endocrinology finding in hypothyroidism, documented in the 2023 eyebrow alopecia review (Nguyen et al., PMID 36183302).

Frontal fibrosing alopecia. FFA is a progressive scarring cicatricial alopecia disproportionately affecting postmenopausal women, with incidence rising globally over the past decade. Eyebrow loss affects up to 96% of FFA patients, preceding scalp hairline recession in 43.7% of cases (Nguyen et al., 2023, PMID 36183302). A 2022 pathogenesis review in Frontiers in Medicine identified immune privilege collapse at the follicle bulge as the central destructive mechanism (Tawfik et al., Front. Med., 2022, PMID 35935789). Early intervention is the only window for preservation. Once scarring is established, follicle loss is irreversible.

The prostaglandin biology underlying hormonal brow loss is covered in depth on the Plume Science Hub page on prostaglandin balance and hair loss. The short version: the ratio of follicle-promoting PGE2 and PGF2-alpha to follicle-suppressing PGD2 shifts unfavorably during hormonal decline, pushing follicles toward quiescence via the GPR44/DP2 receptor. Hormonal changes amplify this imbalance.

Evidence. Estrogen-IGF-1 signaling: Trüeb, 2020 (PMID 32765998). Hertoghe's sign and hypothyroidism: Nguyen et al., 2023 (PMID 36183302). FFA epidemiology: Tawfik et al., 2022 (PMID 35935789).

Plume approach. The cAMP pathway activated by Plume Elite's C2 Complex (forskolin from Coleus forskohlii) is downstream of IGF-1 and supports follicle cell activity when hormonal IGF-1 signals are reduced. For confirmed hormonal conditions including hypothyroidism or FFA, medical evaluation and treatment come first. Plume Elite can support the appearance of brow fullness and promote healthy growth during and after hormonal stabilization.

5. Post-Pregnancy Hair Loss

The problem. Postpartum telogen effluvium is a common, underappreciated cause of brow thinning. Estrogen's decline after delivery releases a cohort of follicles from extended anagen, producing diffuse shedding that peaks around 3–4 months postpartum.

Mechanism. Elevated estrogen during pregnancy keeps follicles in anagen for an extended period. After delivery, the abrupt hormonal withdrawal triggers synchronized follicle entry into telogen, producing the characteristic diffuse shed. A 2024 clinical study in the Journal of Clinical and Aesthetic Dermatology found that 56% of 200 women presenting with postpartum telogen effluvium had concurrent androgenetic alopecia that the shedding episode unmasked, complicating recovery timelines (Galal et al., J. Clin. Aesthet. Dermatol., 2024, PMID 38779373).

Evidence. PMID 38779373 is the most recent large study on postpartum TE, confirming it as an unmasking event for underlying alopecia disorders that would otherwise have presented later. Breastfeeding duration is positively correlated with prolonged TE, likely through continued prolactin-mediated estrogen suppression.

Plume was founded by Lauren after she experienced exactly this: postpartum brow and lash loss that no compliant, peptide-based product existed to address. That formulation gap became the Plume Original Formula.

Plume approach. Both Plume Elite and the Plume Original Formula are prostaglandin-free and compliant with the Health Canada Cosmetic Ingredient Hotlist, making them appropriate cosmetic options postpartum. The peptide-cAMP mechanism supports the dermal papilla environment during the regrowth window, improving the appearance of density as new hairs emerge. The Nourish & Define Brow Pomade provides immediate coverage in the interim.

6. Environmental Damage

The problem. UV radiation, dry air, harsh surfactants, and chemical exfoliants can all compromise the brow follicle micro-environment. The damage accumulates gradually and is easy to attribute to aging.

Mechanism. UV irradiation generates reactive oxygen species (ROS) that damage follicle keratinocytes and deplete the local antioxidant pool. A 2024 review confirmed that UV exposure causes oxidative damage and perifollicular mast cell activation, pushing follicles prematurely into catagen (Dias et al., Int. J. Mol. Sci., 2024, PMID 39125943). ROS-induced disruption of follicle redox homeostasis also impairs hair cycle signaling and can accelerate dermal papilla senescence (Li et al., 2024, PMCID PMC11196958). AHA and retinoid products applied too close to the brow margin disrupt the sebaceous lipid layer protecting the follicle infundibulum; daily use of harsh makeup removers is a compounding mechanical stressor.

Plume approach. Ricinoleic acid from castor oil in Plume Elite's C2 Complex provides a barrier-forming, emollient layer at the follicle surface, helping to preserve the lipid microenvironment under environmental stress. The Q5 peptide actives also support keratin synthesis in emerging hairs, improving structural resilience of new brow growth.

7. Medical Conditions

The problem. Several diagnosable medical conditions cause eyebrow-specific or brow-dominant hair loss that will not respond to topical cosmetic intervention alone.

Alopecia areata (AA) affects eyebrows in 19–63% of patients, presenting as bilateral patchy loss with cadaverized hairs and yellow dots on trichoscopy (Nguyen et al., 2023, PMID 36183302). The mechanism is autoimmune: CD8+ T cells attack anagen follicles after immune privilege collapse. Follicle integrity is preserved, so regrowth is possible but not guaranteed without intervention.

Hypothyroidism classically produces Hertoghe's sign (also documented as Queen Anne's sign): thinning or loss of the lateral third of the eyebrow. This is a non-scarring alopecia driven by altered telogen-anagen ratios in the context of reduced thyroid hormone, which is required for normal follicle cycling. Adequate thyroid hormone replacement has been reported to restore normal hair proportions, though brow-specific regrowth data is limited (PMID 36183302).

Frontal fibrosing alopecia (FFA) frequently presents with isolated brow loss before scalp involvement is detectable, and preceded scalp recession in over 43% of one cohort (PMID 36183302). The mechanism is destructive: inflammation targets the follicle bulge stem cells, causing irreversible scarring. See the hormonal section above for full epidemiology.

Trichotillomania presents as irregular patchy brow loss with hairs of varying lengths. Unlike AA, follicles are mechanically disrupted rather than autoimmune-destroyed, and behavioral psychotherapy is the evidence-based primary treatment.

Evidence. All conditions above are cited in the 2023 comprehensive madarosis review by Nguyen, Hu, and Tosti (PMID 36183302), which remains the most complete clinical reference for eyebrow-specific alopecia etiologies.

Plume approach. For diagnosed medical conditions, Plume Elite is appropriate as a complementary cosmetic support once the underlying condition is under medical management. It improves the appearance of brow fullness and supports healthy follicle conditions in hair units that remain viable. For context on how prostaglandin biology intersects with immune-mediated alopecia, see the prostaglandin balance guide.

8. Chemotherapy and Cancer Treatment Recovery

The problem. Taxane-based regimens (docetaxel, paclitaxel) cause the most dramatic and potentially persistent eyebrow and eyelash loss of any chemotherapy class. CIA affects the brows in the majority of patients receiving these agents.

Mechanism. Taxanes disrupt microtubule assembly in rapidly dividing follicle matrix cells, arresting active anagen growth and forcing follicles into a sudden effluvium. Because eyebrow follicles have a short anagen phase to begin with, taxane-induced disruption can be disproportionately severe relative to the scalp. Docetaxel is associated with persistent chemotherapy-induced alopecia (pCIA) in approximately 23.3% of patients, compared to 10.1% with paclitaxel, representing an 8-fold greater risk of non-regrowth relative to other agents (Fenton et al., European Journal of Cancer, 2021, PMID 33350015).

Regrowth timeline. For most patients, brow regrowth begins 3–6 months after treatment completion (Cancer-Related Alopecia Risk and Treatment, PMC, 2025, PMCID PMC12408754). The lateral third of the brow is the most vulnerable zone and sometimes the last to recover. In cases of pCIA, the lateral third does not fully return. In one observational study of FEC-plus-taxane patients, only 53.5% reported partial eyebrow regrowth; 5.7% reported no regrowth at all in the brow region (Nguyen et al., 2023, PMID 36183302).

Clinical prerequisite. Any cosmetic intervention during or after cancer treatment requires clearance from the oncology team. The treating physician confirms appropriateness given the patient's current protocol and immune status.

Evidence. PMID 33350015 (Fenton et al., 2021) is the most-cited taxane pCIA study; PMCID PMC12408754 (2025) provides the most current regrowth timeline data for CIA.

Plume approach. For survivors cleared by their oncology team, Plume Elite supports the appearance of brow density during the post-treatment regrowth window. No prostaglandin analogs, no harsh actives. Plume is developing dedicated resources for chemo-related brow regrowth (Plume P055, forthcoming). In the interim, the Plume lash serum safety guide covers formulation considerations.

For survivors researching options and concerned about ingredient safety, the 2026 prostaglandin-free serum audit compares 13 brands by INCI and regulatory compliance status, including the February 2026 EU SCCS Opinion 1680/25 which declared isopropyl cloprostenate, DDDE, and MDN unsafe for cosmetic use.

The Plume Brow System

Brow regrowth is a months-long process. While the serum works on follicle biology underneath, the makeup line provides immediate definition above. Used together, they let you see the brow you want during the window when the brow you want is still growing in.

Medical Grade Serum

Plume Elite Lash & Brow Enhancing Serum

The strongest formula. Q5 Peptide Complex and patented C2 Complex (US Patent 11,045,444). For stubborn cases, severe over-plucking, age-related thinning, or post-chemo regrowth.

$150 USD

Shop Elite

Original Formula

Lash & Brow Enhancing Serum

The original Plume formula. Peptide-based, prostaglandin-free, safe postpartum. For mild thinning or maintenance after regrowth.

From $64 USD

Shop Original

Instant Definition

Nourish & Define Refillable Brow Pencil

Precision color for filling sparse spots while regrowth happens underneath. Buy the pencil once, replace the refill. Five shades.

$32 USD

Shop Pencil

Sculpt & Fill

Nourish & Define Brow Pomade

Buildable color for shaping and filling. Powered by the same active, patented ingredients as the serum. Water-resistant, smudge-proof.

$46 USD

Shop Pomade

Set & Densify

Nourish & Set Brow Gel

Pigmented brow gel for instant effect while your brows are regrowing. Defines, densifies, holds. Brushes through sparse hairs for natural fullness.

$36 USD

Shop Gel